Form 4: Gossamer Bio CMO Aranda Receives Substantial Equity Awards

Gossamer Bio's Chief Medical Officer, Richard Aranda, was granted significant equity awards, including restricted stock units and stock options, effective January 2, 2026.

Summary

• Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc. (GOSS), reported the acquisition of 93,750 shares of Common Stock in the form of restricted stock units (RSUs) on January 2, 2026.
• These RSUs were acquired at a price of $0 and will vest in four equal annual installments, contingent upon continuous service to the Issuer.
• Following this transaction, Aranda directly beneficially owns 463,106 shares of Common Stock and indirectly owns 2,539 shares through a family trust.
• Aranda also acquired 562,500 stock options (right to buy) on January 2, 2026, with an exercise price of $2.88 per share.
• These stock options have an expiration date of January 1, 2036.
• The vesting schedule for the stock options dictates that 25% will vest on January 2, 2027, with an additional 1/48th of the total shares vesting on the last day of each subsequent one-month period, subject to continuous service.

Sentiment

Score: 7

Explanation: The filing indicates a significant increase in executive equity ownership through compensatory awards, which generally signals strong alignment between management and shareholder interests and confidence in the company's future. This is a positive signal, though it does not reflect operational performance.

Positives

• The significant equity awards granted to the Chief Medical Officer demonstrate continued commitment and alignment of management's interests with those of shareholders.
• The vesting schedules for both RSUs and stock options incentivize long-term service and performance from a key executive.
• The acquisition of a substantial number of stock options at a fixed exercise price provides a strong incentive for the executive to drive company value above the exercise price.

Industry Context

Executive equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries. It serves to attract, retain, and motivate key talent by aligning their financial interests with the long-term success and shareholder value creation of the company. The size and structure of these awards are typically benchmarked against industry peers and company performance goals.

Comparison to Industry Standards

• The structure of the equity awards, with multi-year vesting schedules for both RSUs and stock options, is consistent with common executive compensation practices in the biotech sector, aiming to foster long-term commitment.
• The grant of RSUs at a $0 price is typical for compensatory awards, representing a direct equity stake, while stock options with an exercise price reflect a future potential gain tied to stock appreciation, both standard components of executive packages in comparable companies.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value creation due to significant equity awards.
• Employees: May signal stability in key leadership, potentially boosting morale and confidence in the company's direction.

Next Steps

• Continued vesting of restricted stock units in four equal annual installments, subject to continuous service.
• Continued vesting of stock options, with 25% vesting on January 2, 2027, and 1/48th monthly thereafter, subject to continuous service.

Key Dates

Recommendation

While this Form 4 filing indicates a positive signal of executive alignment and commitment through substantial equity awards, it does not provide information on the company's operational or financial performance. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive insider activity without making a definitive statement on the stock's fundamental value based solely on this disclosure. Investors should consider this information alongside broader financial reports and market conditions.

Keywords

Gossamer Bio, GOSS, Richard Aranda, Chief Medical Officer, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Equity Awards, Biotechnology